Highnoon Laboratories Limited has reported a solid financial performance for the first quarter ended March 31, 2026, driven by higher sales and improved operational efficiency. The pharmaceutical company posted growth in both revenue and net profit, reflecting continued demand for its products and disciplined cost management.
According to the financial results approved by the Board of Directors in its meeting held on April 29, 2026, the company did not announce any cash dividend, bonus shares, right shares, or any other corporate action for the quarter.
On a consolidated basis, Highnoon Laboratories generated net revenue of Rs. 7.52 billion during the first quarter of 2026, compared with Rs. 7.03 billion in the corresponding period last year. Gross profit rose to Rs. 4.38 billion from Rs. 3.68 billion, highlighting stronger profitability despite higher operating expenses.
The company’s operating profit increased to Rs. 1.88 billion, while profit before tax reached Rs. 1.95 billion, compared with Rs. 1.41 billion a year earlier. After accounting for taxation, net profit attributable to the period stood at Rs. 1.05 billion, marking an increase from Rs. 955 million reported in the same quarter of 2025. Earnings per share (EPS) improved to Rs. 19.78, up from Rs. 18.02 in the corresponding period last year.
The standalone financial statements also reflected positive momentum. Revenue increased to approximately Rs. 6.81 billion, while net profit reached Rs. 956 million, compared with Rs. 916 million in the first quarter of the previous year. Standalone earnings per share improved to Rs. 18.04 from Rs. 17.28.
The company’s financial position remained healthy, with total consolidated assets increasing to over Rs. 21.16 billion as of March 31, 2026, compared with Rs. 19.44 billion at the end of December 2025. Total equity also strengthened to approximately Rs. 14.80 billion, reflecting the impact of higher retained earnings during the quarter.
Highnoon Laboratories also reported improved cash generation from operating activities. Consolidated net cash generated from operations reached approximately Rs. 509 million, reversing the operating cash outflow recorded in the corresponding period last year and reinforcing the company’s liquidity position.
The latest quarterly results demonstrate Highnoon Laboratories’ continued resilience in Pakistan’s pharmaceutical sector, with steady revenue growth, expanding profitability, and a stronger balance sheet positioning the company well for the remainder of the financial year.
